WARD Medical RCT

WARD Medical RCT

Principal Investigator

Katja Kjær Grønbæk, MD, PhD student

Study design
Randomized controlled trial
Sample size
300 participants
Study sites

Rigshospitalet og Bispebjerg Hospital, Odense University Hospital, Aalborg University Hospital and Hvidovre Hospital

Inclusion criteria
  • Inclusion and randomization possible within 12 hours of fulfilling all other inclusion criteria below.
  • Adult patients (≥18 years).
  • At least one (additional) expected overnight stay.
  • High-risk medical admission, defines as EITHER:
    • one or more of the following symptoms or tentative diagnoses: Pneumonia, dyspnea, acute coronary syndrome, new onset heart failure or sepsis WITH two or more of the following deviations in vital signs recorded at one time point within 48 hours of admission:
      • Respiratory rate ≥ 21 min-1 or ≤ 7 min-1
      • Oxygen saturation of arterial hemoglobin ≤ 93 %
      • Pulse rate ≥ 111 min-1 or ≤ 40 min-1
      • Systolic blood pressure ≤ 100 mmHg or > 200 mmHg
      • Temperature > 39 °C or ≤ 35,9 °C
      • Any alteration in mental status
      • Any oxygen supplementation
Study procedures

Included patients will be monitored with WARD equipment after hospital admission and will be monitored during hospitalization. Patients will be randomized to receive either standard treatment where WARD study-data are blinded to the healthcare professionals (nurses etc.) treating the patient (control group) or will have real-time continuous monitored vital parameter data transferred to an alarm-generating App (WARD-CSS) in case of vital parameter deviations, that the nurse responsible for the patient care can access through a provided WARD smartphone (case group).

Outcome

Primary outcome is the amount and duration of physiological parameter deviations between the two groups.

Trial registration
NCT04661748

–  Read more